Keywords: ista, net, loss, widens, 2nd-qtr, usa-based, speciality
ISTA's net loss widens in 2nd-qtr 2004
Article | 19 July 2004
USA-based speciality firm ISTA has posted a 38% rise in second-quarternet loss to $8.3 million, or $0.48 per share, from $6.0 million, or $0.45 per ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
